Autor: |
Schabnam Saied, Konstantinos Prokopidis, Adeoye Adenaya, Masoud Isanejad, Rajiv Sankaranarayanan |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
Frontiers in Cardiovascular Medicine, Vol 11 (2024) |
Druh dokumentu: |
article |
ISSN: |
2297-055X |
DOI: |
10.3389/fcvm.2024.1293537 |
Popis: |
BackgroundThere is controversy in relation to commonly used drugs in heart failure (HF) and their impact on muscle function. The aim of this study was to evaluate the odds of receiving specific medications often used in clinical practice by patients with HF and sarcopenia vs. without sarcopenia.MethodsA systematic literature search of cohort studies via databases (PubMed, Web of Science, Scopus, and Cochrane Library) was conducted from inception until March 2023. To determine if sarcopenia is linked to a higher number of specific HF-related medications, a meta-analysis using a random-effects model was used to calculate the pooled effects.ResultsOur main analyses showed no significant association of sarcopenia with administration of higher HF-related medication count vs. those without sarcopenia. Those with lower appendicular lean mass (ALM) had significantly lower odds of receiving angiotensin converting enzyme inhibitors (ACE-Is)/angiotensin receptor blockers (ARBs) (OR: 0.68, 95%CI 0.50–0.90, I2 = 12%, P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|